

**2 May 2025**

**GEIGER COUNTER LIMITED**  
**(THE "COMPANY")**

**Result of subscription rights exercise for Ordinary Shares**

The Board of the Company announces that applications have been received from shareholders to subscribe for 101,658 new ordinary shares of no par value ("**Ordinary Shares**") at a price of 74.58 pence per share (the "Subscription Price").

The Board have determined however, that due to the Ordinary Share price (being materially lower than the Subscription Price both currently and during the run up to the close of the Subscription Rights exercise, it would not be in the best interests of the Company to issue new shares at this level. As a reference the Ordinary Shares have traded between 28 pence and 36 pence since the beginning of April 2025.

Accordingly, the Company announces that no new Ordinary Shares will be issued as a result of the subscription rights exercise for 2025 and that applicants will be refunded by the Registrar as soon as possible.

For further information, please contact:

**Enquiries**

Manulife | CQS

Craig Cleland

T: +44 (0) 20 7201 5368

Cavendish Capital Markets Limited

Tunga Chigovanyika (Corporate Finance)

T: +44 (0) 20 7397 1915

Daniel Balabanoff / Pauline Tribe (Sales)

T: +44 (0) 20 7220 0517

R&H Fund Services (Jersey) Limited

Jane De Barros

T :+44 (0) 1534 825 259

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROIGZGGKVZFGKZG